![]() ![]() The 10 162 227 vaccine-eligible members of 8 participating US health plans were monitored with administrative data updated weekly and supplemented with medical record review for selected outcomes from December 14, 2020, through June 26, 2021.Įxposures Receipt of BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) COVID-19 vaccination, with a risk interval of 21 days for individuals after vaccine dose 1 or 2 compared with an interval of 22 to 42 days for similar individuals after vaccine dose 1 or 2. Objectives To monitor 23 serious outcomes weekly, using comprehensive health records on a diverse population.ĭesign, Setting, and Participants This study represents an interim analysis of safety surveillance data from Vaccine Safety Datalink. Importance Safety surveillance of vaccines against COVID-19 is critical to ensure safety, maintain trust, and inform policy. ![]() Shared Decision Making and Communication.Scientific Discovery and the Future of Medicine.Health Care Economics, Insurance, Payment. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |